# Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma

> **NCT03722355** · PHASE3 · COMPLETED · sponsor: **Radiation Therapy Oncology Group** · enrollment: 712 (actual)

## Conditions studied

- Glioma
- Glioblastoma Multiforme
- Astrocytoma

## Interventions

- **RADIATION:** Conventional RT
- **RADIATION:** Hyperfractionated RT
- **DRUG:** Carmustine

## Key facts

- **NCT ID:** NCT03722355
- **Lead sponsor:** Radiation Therapy Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1990-11-09
- **Primary completion:** 1994-03-15
- **Final completion:** 2002-10-18
- **Target enrollment:** 712 (ACTUAL)
- **Last updated:** 2019-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03722355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03722355, "Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03722355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*